Loading...
XETR
FRE
Market cap29bUSD
Sep 17, Last price  
46.12EUR
1D
-0.04%
1Q
16.44%
Jan 2017
-37.65%
Name

Fresenius SE & Co KGaA

Chart & performance

D1W1MN
XETR:FRE chart
P/E
20.55
P/S
1.14
EPS
2.24
Div yield, %
2.17%
Shrs. gr., 5y
0.20%
Rev. gr., 5y
-8.81%
Revenues
22.87b
+4.76%
10,776,000,00011,358,000,00012,336,000,00014,164,000,00015,972,000,00016,522,000,00019,508,000,00020,545,000,00023,459,000,00027,995,000,00029,471,000,00033,886,000,00033,530,000,00035,409,000,00036,277,000,00037,077,000,00021,329,000,00021,067,000,00021,833,000,00022,873,000,000
Net income
1.26b
+168.37%
330,000,000410,000,000270,000,000494,000,000622,000,000690,000,000932,000,000988,000,0001,070,000,0001,386,000,0001,560,000,0001,814,000,0002,027,000,0001,883,000,0001,707,000,0001,818,000,0001,372,000,000-594,000,000471,000,0001,264,000,000
CFO
2.70b
+10.13%
1,052,000,0001,296,000,0001,074,000,0001,553,000,0001,911,000,0001,689,000,0002,438,000,0002,320,000,0002,585,000,0003,327,000,0003,574,000,0003,937,000,0003,742,000,0004,263,000,0006,549,000,0005,078,000,0004,198,000,0004,456,000,0002,447,000,0002,695,000,000
Dividend
May 25, 20261.05 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.

Related entities

Subsidiaries (95)
IHSS LIMITED
Labesfal - Laboratorios Almiro SA
MABXIENCE HOLDING, S.L.
MABXIENCE RESEARCH SL
peulejiniuseu kabi kolia
PT Fresenius Kabi Combiphar
PT. Fresenius Kabi Indonesia
QUANTIUM MEDICAL SL
VAMED Aktiengesellschaft
VAMED ENGINEERING GmbH
VAMED HEALTH PROJECTS UK LIMITED
VAMED Management und Service GmbH
VAMED Standortentwicklung und Engineering GmbH
CENTRE DE REPRODUCCIO ASISTIDA DEL VALLES S.L.
Fresenius Medical Care North America Retirement Plan

Key people

Stephan Sturm
Chairman of the Management Board, Chief Executive Officer · since 2017
Independent Deputy Chairman of the Supervisory Board · since 2015
Juergen Goetz
Chief Legal and Compliance Officer, Labor Relations Director, Member of the Management Board · since 2007
Mats Christer Henriksson
Member of the Management Board, Chief Executive Officer of Business Segment Fresenius Kabi · since 2013
Oscar Romero de Paco
Independent Member of the Supervisory Board, Employee Representative · since 2016
D. Michael Albrecht
Independent Member of the Supervisory Board · since 2010
Stefanie Balling
Independent Member of the Supervisory Board, Employee Representative · since 2016
Dario Anselmo Ilossi
Member of the Supervisory Board, Employee Representative · since 2007
Konrad Koelbl
Independent Member of the Supervisory Board · since 2007
Frauke Lehmann
Independent Member of the Supervisory Board, Employee Representative · since 2016
Iris Loew-Friedrich
Independent Member of the Supervisory Board · since 2016
Stefan Schubert
Member of the Supervisory Board, Employee Representative · since 2007
Hauke Stars
Independent Member of the Supervisory Board · since 2016
IPO date
Dec 18, 1986
Employees
315,233
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Else-Kröner-Straße 1
Bad Homburg vor der Höhe, HE 61352
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT